Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Maze Therapeutics, Inc.NASDAQ: MAZE
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $7.11M rose 120.4% year over year, ahead of the +92.0% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 17.1% from the prior quarter. Over 3 fiscal years it compounded at +34.5% a year.
Context
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +120.4% holds above the trailing-twelve-month pace of +92.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 16.4M USD
- Year-over-year change
- +70.0%
- 3-year CAGR
- +34.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.4M | +70.0% |
| FY2024 | 2024-12-31 | 9.65M | +10.3% |
| FY2023 | 2023-12-31 | 8.75M | +29.9% |
| FY2022 | 2022-12-31 | 6.74M | — |
Stock-Based Compensation vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +92.0% is the 3rd highest of 8, against a peer median of +43.2%.
- Stock-based compensation amounts to 101.4% of revenue for MAZE, versus a peer median of 16.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $84.66M USD | +15.0% | -12.3% | 8.4% | |
| LTM Sep 2026 | $72.84M USD | +70.9% | +5.6% | 11.2% | |
| LTM Mar 2026 | $51.03M USD | +21.9% | +65.8% | 11.9% | |
| FY2025 | €26.77M EUR | +647.7% | +129.4% | 597.1% | |
| LTM Mar 2026 | $20.28M USD | +92.0% | +34.5% | 101.4% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $19.67M USD | +177.6% | +77.3% | 20.4% |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $13M USD | +43.2% | +66.3% | 126.0% |
| LTM Mar 2026 | $2.79M USD | +13.0% | +36.8% | — | |
| Peer median (excluding MAZE) | — | +43.2% | +65.8% | 16.2% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.